Point of Care Diagnostics Market to Grow from USD 20.63 Billion in 2026 to USD 31.46 Billion by 2031, at a CAGR of 8.8% – MarketsandMarkets™
Delray Beach, FL, Aug. 24, 2026 (GLOBE NEWSWIRE) -- MarketsandMarkets™ projects the global point of care diagnostics market will grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at a CAGR of 8.8% during the forecast period. Market growth is driven by the rising prevalence of chronic and infectious diseases worldwide, increasing demand for rapid and accurate diagnostic testing, and the growing adoption of decentralized healthcare. The aging population, increasing healthcare utilization, continuous advancements in portable diagnostic technologies, growing adoption of home-based testing, and integration of digital health and connectivity features are further expanding the application of point-of-care diagnostics across hospitals, clinics, and community healthcare settings.
Get PDF Brochure - Market Data & Segmentation: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=106829185
Key Market Highlights
Why This Market Matters
The rising prevalence of chronic and infectious diseases is a major factor driving demand for point-of-care diagnostics. Conditions such as diabetes, cardiovascular diseases, cancer, respiratory disorders, and infectious illnesses require rapid and frequent diagnostic testing for early detection, disease management, and timely treatment decisions. The growing aging population, increasing healthcare expenditure, and demand for decentralized healthcare are further accelerating the adoption of POC diagnostic solutions.
POC diagnostics enable rapid diagnosis and clinical decision-making at or near the patient. The market includes blood glucose monitoring, infectious disease testing, cardiac biomarkers, blood gas and electrolyte analyzers, coagulation testing, HbA1c, urinalysis, pregnancy and fertility tests, molecular diagnostics, and multiplex respiratory panels.
Market Overview
The point-of-care diagnostics market is evolving through advances in molecular diagnostics, immunoassays, biochemistry analyzers, microfluidics, biosensors, and portable testing platforms. These technologies are improving diagnostic speed, accuracy, and accessibility while supporting the growing shift toward decentralized healthcare.
Healthcare infrastructure expansion across emerging economies is also contributing significantly to market growth. Governments and private healthcare providers are investing in hospitals, primary healthcare centers, diagnostic laboratories, and community health facilities to improve access to timely diagnostic services. Increasing healthcare expenditure, expanding health insurance coverage, and digital health initiatives are supporting broader access to diagnostic testing across urban and rural settings.
Analyst Perspective
The growing demand for home-based and decentralized diagnostic testing represents a significant opportunity for point-of-care diagnostics market participants. Patients and healthcare providers are increasingly adopting portable diagnostic devices that deliver rapid and accurate results outside traditional laboratory settings. The expansion of telehealth services, digital health platforms, and connected diagnostic solutions is further supporting remote disease monitoring and timely clinical intervention.
Continuous advancements in portable testing platforms, smartphone-enabled diagnostics, and AI-assisted interpretation are expected to create additional opportunities. Increasing demand for decentralized testing is also encouraging companies to develop compact, connected, and easy-to-use diagnostic systems for hospitals, clinics, community healthcare facilities, and home settings.
However, stringent regulatory requirements for diagnostic device approval remain a significant restraint. Manufacturers must comply with rigorous clinical validation, quality assurance, and performance standards before commercialization, increasing development costs and extending product launch timelines. Differences in regulatory requirements across countries can further complicate global market entry.
Speak to Our Analyst - Get Custom Insights: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=106829185
Segment Analysis
By product, glucose monitoring products account for a significant share of the point-of-care diagnostics market. This category includes blood glucose meters, test strips, lancets, continuous glucose monitoring systems, and related accessories. Increasing diabetes prevalence and growing adoption of self-monitoring and continuous glucose monitoring technologies are supporting demand.
Other important product categories include cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy and fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, and fecal occult testing products.
By end user, hospitals, critical care centers, and urgent care centers hold a significant market share, supported by the high demand for rapid diagnostic testing and timely clinical decision-making. Clinical laboratories remain important end users for routine and specialized testing, while ambulatory care facilities and physician offices are increasingly adopting POC diagnostics to improve patient management and reduce turnaround times.
The home care settings & self-testing segment is witnessing strong growth, driven by increasing adoption of self-testing kits, the rising prevalence of chronic diseases, and growing preference for convenient home-based healthcare.
Regional Analysis
Asia Pacific represents a significant growth opportunity for the point-of-care diagnostics market. The region is rapidly evolving due to economic growth, increasing healthcare expenditure, and stronger government focus on improving access to timely disease diagnosis. Countries such as India, China, and Indonesia are investing in primary healthcare infrastructure, diagnostic capabilities, and decentralized testing services.
The establishment of community health centers, rural clinics, and modern hospitals is increasing adoption of point-of-care diagnostic technologies for infectious diseases, chronic conditions, and emergency care. Private healthcare providers are also investing in digital diagnostics, connected testing platforms, and integrated healthcare solutions. Demand is increasing for blood glucose meters, rapid diagnostic tests, HbA1c analyzers, cardiac marker testing systems, blood gas analyzers, and handheld molecular diagnostic devices.
Key Industry Trends
Competitive Landscape
The point-of-care diagnostics market is moderately consolidated, with leading players accounting for approximately 60–65% of the global market in 2025. Key market participants include Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, QuidelOrtho Corporation, bioMérieux SA, and Werfen S.A. These companies maintain their leadership through diversified product portfolios, continuous product innovation, strong regulatory capabilities, and extensive global distribution networks.
The market presents significant opportunities across North America, Europe, and Asia Pacific, particularly in China, India, Japan, and South Korea. Growth in these markets is supported by expanding healthcare infrastructure, increasing adoption of decentralized diagnostics, rising healthcare investments, and strategic expansion of manufacturing and commercial operations.
Related Reports
US Point of Care Diagnostics Market
UK Point of Care Diagnostics Market